NICE recommends cenobamate for treatment of adult epilepsy patients in UK
Epilepsy affects over 600,000 people in the UK, which is approximately one in every 100 people
Read More
Tag: Ontozry
Ontozry scores MHRA authorisation for focal-onset seizures
Drug approved to treat adult patients with epilepsy which has not been adequately controlled with at least two anti-epileptic therapies
Read More
EC approval for Ontozry
The drug offers new hope for epilepsy patients with focal-onset seizures
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
